GlassScriptPhysician profile
Kuocheng Wang
NPI 1316979651
$14,406.66
in general payments reported to CMS, 2019-2025
29 companies · $1,841 in 2025
The $1,841 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,252 · 2020: $1,567 · 2021: $2,653 · 2022: $1,799 · 2023: $1,685 · 2024: $1,611 · 2025: $1,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,130 · Education: $6.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,130.18 |
| Education | $6.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,444.83 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Gilead Sciences, INC. | $2,036.80 | 2019-2025 | Vemlidy, Epclusa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,402.84 | 2019-2025 | Jardiance |
| Abbvie INC. | $1,278.26 | 2019-2024 | Viberzi, Linzess |
| Amgen INC. | $1,062.57 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $674.77 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $609.88 | 2019-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $575.19 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $569.66 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $532.72 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $494.14 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $377.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $350.25 | 2019-2022 | |
| Horizon Therapeutics Plc | $271.59 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $249.87 | 2019-2023 | Verquvo, Steglatro, Steglujan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $217.66 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $188.48 | 2019-2023 | |
| Globus Medical, INC. | $165.85 | 2025 | Senza |
| Sanofi-Aventis U.S. LLC | $140.01 | 2019 | |
| Exact Sciences Corporation | $132.38 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $114.14 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $113.90 | 2022-2025 | Zoryve, Livalo |
| Novartis Pharmaceuticals Corporation | $92.40 | 2021 | |
| Allergan, INC. | $81.24 | 2020 | |
| Vifor Pharma, INC. | $64.97 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $59.21 | 2022-2024 | Nuplazid |
| Ibsa Pharma INC. | $46.11 | 2021 | |
| Seqirus USA INC | $32.91 | 2019-2025 | Flucelvax |
| Sumitomo Pharma America, INC. | $26.25 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kuocheng Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.